The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect
Cancer Letters · 2024-08 · 598 · 217123
DOI: 10.1016/j.canlet.2024.217123 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Liliang Xia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, PR China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Jiaotong University, Shanghai Chest Hospital, National Health Commission of the People's Republic of China.
Abstract (Originalsprache)
Immune-checkpoint inhibitors (ICIs), including anti-PD-1/PD-L1 therapeutic antibodies, have markedly enhanced survival across numerous cancer types. However, the limited number of patients with durable benefits creates an urgent need to identify response biomarkers and to develop novel strategies so as to improve response. It is widely recognized that the gut microbiome is a key mediator in shaping immunity. Additionally, the gut microbiome shows significant potential in predicting the response to and enhancing the efficacy of ICI immunotherapy against cancer. Recent studies encompassing mechanistic analyses and clinical trials of microbiome-based therapy have shown a cause-and-effect relationship between the gut microbiome and the modulation of the ICI immunotherapeutic response, greatly contributing to the establishment of novel strategies that will improve response and overcome resistance to ICI treatment. In this review, we outline the current state of research advances and discuss the future directions of utilizing the gut microbiome to enhance the efficacy of ICI immunotherapy against tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, PR China.
- Shanghai Institute of Immunology, Department of Immunology and Microbiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiaotong University School of Medicine, Shangh…
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, PR China. Electronic address: shunlu@sjtu.edu.cn.
Förderung
- Shanghai Jiaotong University
- Shanghai Chest Hospital
- National Health Commission of the People's Republic of China
- National Natural Science Foundation of China
Zitieren
APA
Xia, L., Zhu, X., Wang, Y., & Lu, S. (2024). The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect. Cancer Letters, 598, 217123. https://doi.org/10.1016/j.canlet.2024.217123
Vancouver
Xia L, Zhu X, Wang Y, Lu S. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect. Cancer Letters. 2024;598:217123. doi:10.1016/j.canlet.2024.217123
BibTeX
@article{Xia2024,
author = {Xia, Liliang and Zhu, Xiaokuan and Wang, Ying and Lu, Shun},
title = {The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect},
journal = {Cancer Letters},
year = {2024},
volume = {598},
pages = {217123},
doi = {10.1016/j.canlet.2024.217123}
}
EUVIMED